The Manufacturers Life Insurance Company boosted its position in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 2.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,485 shares of the biopharmaceutical company’s stock after purchasing an additional 743 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.07% of MacroGenics worth $463,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MGNX. Teachers Advisors LLC boosted its stake in MacroGenics by 28.1% during the 1st quarter. Teachers Advisors LLC now owns 315,450 shares of the biopharmaceutical company’s stock valued at $5,867,000 after acquiring an additional 69,277 shares during the last quarter. Vanguard Group Inc. boosted its stake in MacroGenics by 3.4% during the 1st quarter. Vanguard Group Inc. now owns 1,352,864 shares of the biopharmaceutical company’s stock valued at $25,163,000 after acquiring an additional 44,680 shares during the last quarter. Geode Capital Management LLC boosted its stake in MacroGenics by 4.4% during the 1st quarter. Geode Capital Management LLC now owns 260,670 shares of the biopharmaceutical company’s stock valued at $4,847,000 after acquiring an additional 10,983 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in MacroGenics during the 1st quarter valued at $810,000. Finally, Renaissance Technologies LLC bought a new position in MacroGenics during the 1st quarter valued at $2,435,000. 82.75% of the stock is owned by institutional investors and hedge funds.
MacroGenics, Inc. (NASDAQ:MGNX) opened at $19.80 on Monday. MacroGenics, Inc. has a 52-week low of $14.36 and a 52-week high of $28.90.
MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.09) by ($0.19). MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The business had revenue of $1.70 million during the quarter, compared to the consensus estimate of $5.50 million. During the same quarter in the previous year, the business posted ($0.97) earnings per share. The company’s quarterly revenue was down 48.5% compared to the same quarter last year. research analysts anticipate that MacroGenics, Inc. will post -0.7 earnings per share for the current fiscal year.
In other news, SVP Jon Marc Wigginton sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $20.00, for a total value of $100,000.00. Following the transaction, the senior vice president now directly owns 35,000 shares in the company, valued at approximately $700,000. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 8.30% of the company’s stock.
A number of research analysts have commented on the stock. ValuEngine downgraded shares of MacroGenics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 14th. Citigroup Inc. increased their price objective on shares of MacroGenics from $18.00 to $22.00 and gave the company a “neutral” rating in a research note on Friday, November 10th. Cowen Inc reiterated a “buy” rating on shares of MacroGenics in a research note on Wednesday, October 25th. Zacks Investment Research upgraded shares of MacroGenics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $34.00 price objective on shares of MacroGenics in a research note on Tuesday, September 12th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $30.10.
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.